Harmony Biosciences Holdings Inc

HRMY

26.540USD

-0.900-3.28%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Harmony Biosciences Holdings Inc's Score

Industry at a Glance

Industry Ranking

28 / 157

Overall Ranking

98 / 4542

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Harmony Biosciences Holdings Inc Highlights

StrengthsRisks

Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 49.21% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 868.45M.

Undervalued

The company’s latest PE is 9.62, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 50.78M shares, decreasing 10.66% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 228.51K shares of this stock.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

42.000

Target Price

+54.98%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Harmony Biosciences Holdings Inc is 9.54, ranking 2 out of 157 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 243.78M, representing a year-over-year increase of 21.12%, while its net profit experienced a year-over-year increase of 54.55%.

Score

Industry at a Glance

Previous score

9.54

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.99

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.69

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Harmony Biosciences Holdings Inc is 7.90, ranking 40 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 9.62, which is 108.98% below the recent high of 20.09 and 20.91% above the recent low of 7.60.

Score

Industry at a Glance

Previous score

7.90

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 28/157

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Harmony Biosciences Holdings Inc is 7.09, ranking 118 out of 157 in the Pharmaceuticals industry. The average price target is 47.00, with a high of 62.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

7.09

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Harmony Biosciences Holdings Inc is 6.06, ranking 133 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 28.32 and the support level at 25.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.50

Change

-0.44

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Harmony Biosciences Holdings Inc is 7.00, ranking 42 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 88.16%, representing a quarter-over-quarter increase of 5.70%. The largest institutional shareholder is The Vanguard, holding a total of 4.80M shares, representing 8.30% of shares outstanding, with 1.68% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Marshman Fund Trust ii

6.05M

--

BlackRock Institutional Trust Company, N.A.

5.84M

+1.23%

The Vanguard Group, Inc.

Star Investors

5.09M

-0.27%

Fidelity Management & Research Company LLC

3.85M

-17.95%

HBM Partners AG

2.15M

--

American Century Investment Management, Inc.

1.67M

+11.20%

Dimensional Fund Advisors, L.P.

1.69M

+6.91%

State Street Investment Management (US)

1.65M

+1.50%

LSV Asset Management

1.59M

+7.15%

Arrowstreet Capital, Limited Partnership

1.30M

+42.83%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Harmony Biosciences Holdings Inc is 8.08, ranking 29 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Harmony Biosciences Holdings Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Harmony Biosciences Holdings Inc

HRMY

7.71 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

8.81 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Innoviva Inc

INVA

8.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mckesson Corp

MCK

8.40 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Jazz Pharmaceuticals PLC

JAZZ

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment